Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 2

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 2
---
 to inadequate insurance coverage  

  Risks relating to failure in safeguarding our computer network system  

  Risks relating to outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease  

Risks Related to Our Corporate Structure

  Risks relating to our Class B shareholders have higher voting rights  

Risks Related to our Securities

  Risks relating to certain existing shareholders have substantial influence over our Company and their interests may not be aligned with the interests of our other shareholders  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Risks relating to conduct substantially all of our operations outside the United States  

  Risks relating to adopt certain home country practices or take advantage of certain reduced reporting requirements  
  We have ceased to qualify as an “emerging growth company” and will incur increased costs as a result.               

Risks Related to the Preclinical and Clinical
Development of Our Drug Candidates

We currently do not generate revenue from
product sales and may never become profitable; unless we can raise more capital through additional financings, of which there can be no
guarantee.

Our ability to generate revenue
and become profitable depends upon our ability to successfully complete the development of, and obtain the necessary regulatory approvals
for, the drug candidates in our Lead Projects and any future drug candidates we may develop, as we do not currently have any drugs that
are available for commercial sale. We expect to continue to incur losses before commercialization of our drug candidates and any future
drug candidates. None of our drug candidates has been approved for marketing in the U. S., Europe, the PRC or any other jurisdictions and
may never receive such approval. Our ability to generate revenue and achieve profitability is dependent on our ability to complete the
development of our drug candidates and any future drug candidates we develop in our portfolio, obtain necessary regulatory approvals,
and have our drugs products under development manufactured and successfully marketed, of which there can be no guarantee. We may not be
able to generate a profit until our drug candidates become profitable.

Even if we receive regulatory
approval and marketing authorization for one or more of our drug candidates or one or more of any future drug candidates for commercial
sale, a potential product may not generate revenue at all unless we are successful in:

  developing a sustainable and scalable manufacturing process for our drug candidates and any approved products, including establishing and maintaining commercially viable supply relationships wi...  
  launching